1. Home
  2. HIW vs RCUS Comparison

HIW vs RCUS Comparison

Compare HIW & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HIW

Highwoods Properties Inc.

HOLD

Current Price

$32.43

Market Cap

3.5B

Sector

Real Estate

ML Signal

HOLD

Logo Arcus Biosciences Inc.

RCUS

Arcus Biosciences Inc.

HOLD

Current Price

$27.94

Market Cap

3.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HIW
RCUS
Founded
1978
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
3.6B
IPO Year
1995
2018

Fundamental Metrics

Financial Performance
Metric
HIW
RCUS
Price
$32.43
$27.94
Analyst Decision
Hold
Buy
Analyst Count
7
10
Target Price
$27.57
$31.90
AVG Volume (30 Days)
1.6M
985.3K
Earning Date
04-28-2026
05-05-2026
Dividend Yield
8.43%
N/A
EPS Growth
54.26
N/A
EPS
0.29
N/A
Revenue
$806,112,000.00
$247,000,000.00
Revenue This Year
$6.03
N/A
Revenue Next Year
$3.58
$45.62
P/E Ratio
$113.72
N/A
Revenue Growth
N/A
N/A
52 Week Low
$20.45
$8.88
52 Week High
$35.44
$31.74

Technical Indicators

Market Signals
Indicator
HIW
RCUS
Relative Strength Index (RSI) 52.34 51.56
Support Level $32.37 $25.94
Resistance Level $33.88 $28.72
Average True Range (ATR) 0.77 1.45
MACD -0.23 -0.11
Stochastic Oscillator 10.41 49.26

Price Performance

Historical Comparison
HIW
RCUS

About HIW Highwoods Properties Inc.

Highwoods Properties Inc is a fully integrated office REIT that owns, develops, acquires, leases, and manages office properties mainly in the best business districts of Atlanta, Charlotte, Dallas, Nashville, Orlando, Raleigh, Richmond, and Tampa. Its principal business is the operation, acquisition, and development of rental office properties, with no material inter-segment transactions. The Company evaluates performance by geographic location, and the operating results by geographic grouping are regularly reviewed by the chief operating decision maker. The core portfolio consists mainly of office properties in its key markets, with the majority of revenue derived from its Raleigh properties.

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.

Share on Social Networks: